J
Joseph F. Merola
Researcher at Brigham and Women's Hospital
Publications - 347
Citations - 6327
Joseph F. Merola is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Medicine & Psoriasis. The author has an hindex of 32, co-authored 248 publications receiving 4005 citations. Previous affiliations of Joseph F. Merola include University Hospital of Wales & Harvard University.
Papers
More filters
Journal ArticleDOI
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip J. Mease,Stephen Hall,Oliver FitzGerald,Désirée van der Heijde,Joseph F. Merola,Francisco Avila-Zapata,Dorota Cieślak,Daniela Graham,Cunshan Wang,Sujatha Menon,Thijs Hendrikx,Keith S. Kanik +11 more
TL;DR: The efficacy of tofacitinib was superior to that of placebo at month 3 in patients with psoriatic arthritis who had previously had an inadequate response to conventional synthetic DMARDs.
Journal ArticleDOI
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A. Singh,Gordon H. Guyatt,Alexis Ogdie,Dafna D. Gladman,Chad L. Deal,Atul Deodhar,Maureen Dubreuil,Jonathan Dunham,M. Elaine Husni,Sarah Kenny,Jennifer Kwan-Morley,Janice Lin,Paula Marchetta,Philip J. Mease,Joseph F. Merola,Julie Miner,Christopher T. Ritchlin,Bernadette C. Siaton,Benjamin J Smith,Abby S. Van Voorhees,Anna Helena Jonsson,Amit Aakash Shah,Nancy Sullivan,Marat Turgunbaev,Laura C. Coates,Alice B. Gottlieb,Marina Magrey,W. Benjamin Nowell,Ana Maria Orbai,Soumya M. Reddy,Jose U. Scher,Evan Siegel,Michael Siegel,Jessica A. Walsh,Amy S. Turner,James Reston +35 more
TL;DR: The 2018 ACR/NPF guideline as mentioned in this paper provides evidence-based guidelines for the pharmacologic and non-pharmacologic treatment of psoriatic arthritis (PsA) using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology.
Journal ArticleDOI
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh,Gordon H. Guyatt,Alexis Ogdie,Dafna D. Gladman,Chad L. Deal,Atul Deodhar,Maureen Dubreuil,Jonathan Dunham,M. Elaine Husni,Sarah Kenny,Jennifer Kwan-Morley,Janice Lin,Paula Marchetta,Philip J. Mease,Joseph F. Merola,Julie Miner,Christopher T. Ritchlin,Bernadette C. Siaton,Benjamin J Smith,Abby S. Van Voorhees,Anna Helena Jonsson,Amit Aakash Shah,Nancy Sullivan,Marat Turgunbaev,Laura C. Coates,Alice B. Gottlieb,Marina Magrey,W. Benjamin Nowell,Ana Maria Orbai,Soumya M. Reddy,Jose U. Scher,Evan Siegel,Michael Siegel,Jessica A. Walsh,Amy S. Turner,James Reston +35 more
TL;DR: To develop an evidence‐based guideline for the pharmacologic and nonpharmacologic treatment of psoriatic arthritis (PsA), as a collaboration between the American College of Rheumatology and the National Psoriasis Foundation (NPF).
Journal ArticleDOI
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
TL;DR: A revolution in the available treatments for psoriasis has led to beneficial clinical responses in a notable proportion of patients who very often achieve remission, but these accomplishments are yet to be matched in psoriatic arthritis (PsA), for which no new therapies have so far demonstrated superiority over established therapies.
Journal ArticleDOI
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.
Laura C. Coates,Oliver FitzGerald,Joseph F. Merola,Josef S Smolen,Leonieke J J van Mens,Heidi Bertheussen,Wolf-Henning Boehncke,Kristina Callis Duffin,Willemina Campbell,Maarten de Wit,Dafna D. Gladman,Alice B. Gottlieb,Jana James,Arthur Kavanaugh,Lars Erik Kristensen,Tore K Kvien,Thomas A. Luger,Neil McHugh,Philip J. Mease,Peter Nash,Alexis Ogdie,Cheryl F. Rosen,Vibeke Strand,William Tillett,Douglas J. Veale,Philip S. Helliwell +25 more
TL;DR: A meeting was convened by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) to further the development of consensus among physicians and patients regarding composite disease activity measures and targets in psoriatic arthritis (PsA).